IP Library Granted Patent US 12,434,072
Granted Patent B2
US 12,434,072 · App. 18/642,364 · Granted Oct 7, 2025

Methods and systems for neural stimulation via visual, auditory and peripheral nerve stimulations

Inventors: Zachary John Hambrecht Malchano (Boston, MA); Martin Warren Williams (San Francisco, CA)
Assignee: COGNITO THERAPEUTICS, INC.
A61N5/0622A61B5/0036A61B5/16A61B5/377A61B5/378A61B5/38A61B5/4088A61B5/4836A61M21/00A61N1/0456A61N1/36025A61N1/36036A61N1/36082A61N1/36092A61N1/36132A61N5/0618G02C11/10H05B47/105A61B3/113A61B5/024A61B5/05A61B5/163A61B5/168A61B5/375A61B5/398A61B5/4848A61B5/6803A61M2021/0027A61M2021/0044A61M2021/0072A61M2205/3375A61N1/0551A61N2005/0626A61N2005/0627A61N2005/0629A61N2005/0648A61N2005/0652A61N2005/0659A61N2005/0661A61N2005/0662A61N2005/0663A61N2005/0667G02C2200/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,434,072
App. No.
18/642,364
Granted
Oct 7, 2025
Kind
B2
Abstract

Systems and methods of the present disclosure are directed to systems and methods for treating cognitive dysfunction in a subject in need thereof. The system can include a light source and a speaker. A visual neural stimulation system provides, via the light source, visual stimulation having a first value of a first parameter. An auditory neural stimulation system provides, via the speaker, audio stimulation having a second value of the second parameter. A stimuli orchestration component selects, for a first time interval, one of the visual stimulation or the audio stimulation to vary based on a policy, selects, for the first time interval, the other of the visual stimulation or the audio stimulation to keep constant based on the policy, and provides causes the one of the visual neural stimulation system or the auditory neural stimulation system to vary the one of the visual stimulation or the audio stimulation.

Claims (36)

1. A method for treating mild cognitive impairment or Alzheimer's disease or benefiting a cognitive function of a brain of a subject in need thereof via a system, the method comprising:

(a) using a first light source to generate a first light pulse and using a second light source to generate a second light pulse, wherein said first light source or said second light source comprises a filtering component configured to selectively transmit a portion of an initial spectral range of the first light pulse or the second light pulse;

(b) determining an attention level of the subject by:

(i) performing eye tracking of an eye of the subject via a feedback sensor; or

(ii) determining an orientation of at least one of a head or a body of the subject; and

(c) emitting the first light pulse and the second light pulse to the subject, wherein the first light pulse and the second light pulse are emitted at a 40 Hertz (Hz) frequency, thereby slowing a progression of mild cognitive impairment or Alzheimer's disease, or thereby benefiting the cognitive state or function of the brain of the subject; wherein the determining the attention level of the subject comprises comparing, via a feedback monitor, a direction or a movement of an eye of the subject to a historical eye direction or an eye movement of the subject based on a threshold.

2. The method of claim 1 , wherein the first light pulse emits a first plurality of light waves, and the second light pulse emits a second plurality of light waves, wherein the first plurality light waves or the second plurality of light waves comprise light waves having one or more wavelengths ranging from 380 nanometers (nm) to 750 nanometers (nm).

3. The method of claim 2 , wherein the first plurality of light waves and the second plurality of light waves do not comprise ultraviolet or infra-red light.

4. The method of claim 2 , wherein the first plurality of light waves comprises wavelengths of a different color than the wavelengths of the light waves of the second plurality of light waves.

5. The method of claim 1 , wherein the first light source and the second light source are polychromatic light-emitting diodes, organic light-emitting diodes, or light bulbs.

6. The method of claim 1 , wherein a duty cycle of the first light pulse and the second light pulse is less than or equal to fifty percent.

7. The method of claim 1 , further comprising applying a phase offset to the light pulses emitted from the second light source ranging from 0 to 180 degrees with respect to the light pulses emitted from the first light source while keeping the light pulses emitted from the first light source constant.

8. The method of claim 1 , wherein the performing eye tracking of the eye of the subject further comprises measuring via the feedback sensor and determining via a feedback monitor operatively coupled to the feedback sensor:

(i) a pupil size of the subject;

(ii) a movement of a fovea or a pupil of the eye of the subject;

(iii) an eye gaze direction of the eye of the subject;

(iv) a pupil position of the eye of the subject;

(v) a rate of change in an eye pupil position of the eye of the subject;

(vi) a pupil or corneal reflection of the eye of the subject; or

(vii) a distance between the subject and the first light source and the second light source; and

wherein the feedback sensor comprises a camera, a video camera, an infrared source that sends light towards the eyes, an accelerometer, a gyroscope, a proximity sensor, or a motion detector.

9. The method of claim 1 , wherein the performing the eye tracking of the eye of the subject further comprises adjusting, responsive to a movement of a fovea of the eye of the subject, the first light source or the second light source to direct the first light pulse or the second light pulse toward the eye of the subject within 15 degrees of the fovea of the eye of the subject.

10. The method of claim 1 , wherein the filtering component comprises a polarizer, a filter, a prism, a photochromic material, an electrochromic glass, an electrochromic plastic, an absorptive filter, an interference filter, a shutter, a dichroic milter, or a light attenuator.

11. The method of claim 1 , wherein the determining the attention level of the subject further comprises determining, via the feedback monitor, that:

(a) a level of eye movement of the eye of the subject is greater than a threshold; or

(b) a gaze direction of the eye of the subject is outside a direct visual field of the light source.

12. The method of claim 1 , wherein the emitting comprises:

(a) toggling, via a light adjustment module, between the first light pulse emitted from the first light source and the second light pulse emitted from the second light source to produce a stroboscopic flicker between the first light pulse and the second light pulse; and

(b) alternating emission of the first light pulse and emission of the second light pulse to the eye of the subject, wherein a color of the first light pulse emitted from the first light source is different from the color of the second light pulse emitted from the second light source.

13. The method of claim 1 , wherein the method comprises applying the first light pulse and the second light pulse to the subject daily for about 1 hour per day.

14. The method of claim 13 , wherein the applying comprises applying the first light pulse and the second light pulse to the subject in multiple sessions per day, wherein a duration of each session of the multiple sessions is less than 1 hour.

15. The method of claim 1 , further comprising emitting the first light pulse and the second light pulse to the subject at least once a day for a period of at least about one month.

16. The method of claim 1 , further comprising executing an application for

(a) generating the first light pulse; or

(b) adjusting the frequency, a brightness, or a color of the first light pulse or the second light pulse,

wherein the application is executed via a stimulus-emitting device that is not supported by the subject or via a second device wirelessly and communicatively coupled to the stimulus-emitting device.

Assignments (2)
SECURITY INTEREST Recorded Jan 23, 2026
From: COGNITO THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC.
Reel/Frame 073568/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2024
From: MALCHANO, ZACHARY JOHN HAMBRECHT; WILLIAMS, MARTIN WARREN
To: COGNITO THERAPEUTICS, INC.
Reel/Frame 067256/0214 →
Continuity (15)
Continuation 16919975 · Jul 2, 2020
Continuation 16427276 · May 30, 2019
Continuation 15816238 · Nov 17, 2017
Provisional Application 62431725 · Dec 8, 2016
Provisional Application 62431720 · Dec 8, 2016
Provisional Application 62431698 · Dec 8, 2016
Provisional Application 62431702 · Dec 8, 2016
Provisional Application 62423536 · Nov 17, 2016
Provisional Application 62423452 · Nov 17, 2016
Provisional Application 62423569 · Nov 17, 2016
Provisional Application 62423598 · Nov 17, 2016
Provisional Application 62423532 · Nov 17, 2016
Provisional Application 62423557 · Nov 17, 2016
Provisional Application 62423517 · Nov 17, 2016
Related Publication 20240269481A1 · Aug 15, 2024
References Cited (400)
US 4315502A · Gorges · 1982 [cited by applicant]
US 4449047A · Monroe · 1984 [cited by applicant]
US 4456910A · DiMassimo et al. · 1984 [cited by applicant]
US 4674852A · Tanaka · 1987 [cited by applicant]
US 5151687A · Younger · 1992 [cited by applicant]
US 5534953A · Schmielau · 1996 [cited by applicant]
US 5659287A · Donati et al. · 1997 [cited by applicant]
US 5923398A · Goldman · 1999 [cited by applicant]
US 5934967A · Brown et al. · 1999 [cited by applicant]
US 6066163A · John · 2000 [cited by applicant]
US 6071229A · Rubins · 2000 [cited by applicant]
US 6113537A · Castano · 2000 [cited by applicant]
US 6167298A · Levin · 2000 [cited by applicant]
US 6206537B1 · Hauck · 2001 [cited by applicant]
US 6234953B1 · Thomas et al. · 2001 [cited by applicant]
US 6443977B1 · Jaillet · 2002 [cited by applicant]
US 6463328B1 · John · 2002 [cited by applicant]
US 6539263B1 · Schiff et al. · 2003 [cited by applicant]
US 6733490B1 · Falsini et al. · 2004 [cited by applicant]
US 7010356B2 · Jog et al. · 2006 [cited by applicant]
US 7361074B1 · Periman et al. · 2008 [cited by applicant]
US 7446785B1 · Hewlett et al. · 2008 [cited by applicant]
US 7569545B2 · Li et al. · 2009 [cited by applicant]
US 7645226B2 · Shealy et al. · 2010 [cited by applicant]
US 7715910B2 · Hargrove et al. · 2010 [cited by applicant]
US 7748846B2 · Todd · 2010 [cited by applicant]
US 7769439B2 · Vesely et al. · 2010 [cited by applicant]
US 8070669B2 · Brunelle et al. · 2011 [cited by applicant]
US 8083392B2 · Chien · 2011 [cited by applicant]
US 8121694B2 · Molnar et al. · 2012 [cited by applicant]
US 8239030B1 · Hagedorn et al. · 2012 [cited by applicant]
US 8267851B1 · Kroll · 2012 [cited by applicant]
US 8280502B2 · Hargrove et al. · 2012 [cited by applicant]
US 8328420B2 · Abreu · 2012 [cited by applicant]
US 8380314B2 · Panken et al. · 2013 [cited by applicant]
US 8396545B2 · Berridge et al. · 2013 [cited by applicant]
US 8423144B2 · Tass et al. · 2013 [cited by applicant]
US 8543219B2 · Tass · 2013 [cited by applicant]
US 8577470B2 · Assaf et al. · 2013 [cited by applicant]
US 8579793B1 · Honeycutt et al. · 2013 [cited by applicant]
US 8591392B2 · Bentwich et al. · 2013 [cited by applicant]
US 8636640B2 · Chang · 2014 [cited by applicant]
US 8700167B2 · Sabel · 2014 [cited by applicant]
US 8845704B2 · Dunning et al. · 2014 [cited by applicant]
US 8892207B2 · Nelson et al. · 2014 [cited by applicant]
US 8894696B2 · Hurst · 2014 [cited by applicant]
US 8914119B2 · Wu et al. · 2014 [cited by applicant]
US 8932218B1 · Thompson · 2015 [cited by applicant]
US 8942809B2 · Assaf et al. · 2015 [cited by applicant]
US 9119583B2 · Tass · 2015 [cited by applicant]
US 9272118B1 · Acton · 2016 [cited by applicant]
US 9302069B2 · Tass et al. · 2016 [cited by applicant]
US 9629976B1 · Acton · 2017 [cited by applicant]
US 10159816B2 · Tsai et al. · 2018 [cited by applicant]
US 10265497B2 · Tsai et al. · 2019 [cited by applicant]
US 10279192B2 · Malchano et al. · 2019 [cited by applicant]
US 10293177B2 · Malchano et al. · 2019 [cited by applicant]
US 10307611B2 · Malchano et al. · 2019 [cited by applicant]
US 10518063B1 · Noftsker · 2019 [cited by applicant]
US 10682490B2 · Tsai et al. · 2020 [cited by applicant]
US 10702705B2 · Malchano et al. · 2020 [cited by applicant]
US 10745479B2 · Jaminet et al. · 2020 [cited by applicant]
US 10843006B2 · Malchano et al. · 2020 [cited by applicant]
US 10960225B2 · Adaikkan et al. · 2021 [cited by applicant]
US 11141604B2 · Malchano et al. · 2021 [cited by applicant]
US 11241586B2 · Tsai et al. · 2022 [cited by applicant]
US 20010027278A1 · Kaufman et al. · 2001 [cited by applicant]
US 20010039012A1 · Lapidus · 2001 [cited by applicant]
US 20040097841A1 · Saveliev et al. · 2004 [cited by applicant]
US 20040158119A1 · Osorio et al. · 2004 [cited by applicant]
US 20050070977A1 · Molina · 2005 [cited by applicant]
US 20050234286A1 · Riehl et al. · 2005 [cited by applicant]
US 20060173510A1 · Besio et al. · 2006 [cited by applicant]
US 20070038142A1 · Todd et al. · 2007 [cited by applicant]
US 20070156182A1 · Castel et al. · 2007 [cited by applicant]
US 20070179557A1 · Maschino et al. · 2007 [cited by applicant]
US 20070191727A1 · Fadem · 2007 [cited by applicant]
US 20070218994A1 · Goto et al. · 2007 [cited by applicant]
US 20070225773A1 · Shen et al. · 2007 [cited by applicant]
US 20070253561A1 · Williams et al. · 2007 [cited by applicant]
US 20080055541A1 · Coulter et al. · 2008 [cited by applicant]
US 20080181882A1 · Hahn · 2008 [cited by applicant]
US 20080227139A1 · Deisseroth et al. · 2008 [cited by applicant]
US 20080255949A1 · Genco et al. · 2008 [cited by applicant]
US 20090005837A1 · Olmstead · 2009 [cited by applicant]
US 20090023977A1 · Sperling et al. · 2009 [cited by applicant]
US 20090030476A1 · Hargrove · 2009 [cited by applicant]
US 20090093403A1 · Zhang et al. · 2009 [cited by applicant]
US 20090153800A1 · Bassi et al. · 2009 [cited by applicant]
US 20090237563A1 · Doser · 2009 [cited by applicant]
US 20090270776A1 · Chang · 2009 [cited by applicant]
US 20100013402A1 · Chaffai et al. · 2010 [cited by applicant]
US 20100109541A1 · Roberts et al. · 2010 [cited by applicant]
US 20100174344A1 · Dadd et al. · 2010 [cited by applicant]
US 20100190129A1 · Paz · 2010 [cited by applicant]
US 20100217358A1 · Hebert et al. · 2010 [cited by applicant]
US 20100241021A1 · Morikawa et al. · 2010 [cited by applicant]
US 20100274329A1 · Bradley et al. · 2010 [cited by applicant]
US 20110066586A1 · Sabel et al. · 2011 [cited by applicant]
US 20110105998A1 · Zhang et al. · 2011 [cited by applicant]
US 20110122396A1 · Ivaldi et al. · 2011 [cited by applicant]
US 20110152967A1 · Simon et al. · 2011 [cited by applicant]
US 20110280932A1 · Garcia et al. · 2011 [cited by applicant]
US 20120016174A1 · De Taboada et al. · 2012 [cited by applicant]
US 20120065709A1 · Dunning et al. · 2012 [cited by applicant]
US 20120150545A1 · Simon · 2012 [cited by applicant]
US 20120251989A1 · Wetmore · 2012 [cited by examiner]
US 20120289869A1 · Tyler · 2012 [cited by applicant]
US 20130066392A1 · Simon et al. · 2013 [cited by applicant]
US 20130066395A1 · Simon et al. · 2013 [cited by applicant]
US 20130083173A1 · Geisner et al. · 2013 [cited by applicant]
US 20130084299A1 · Maze et al. · 2013 [cited by applicant]
US 20130211238A1 · Decharms · 2013 [cited by applicant]
US 20130216055A1 · Wanca · 2013 [cited by applicant]
US 20130253338A1 · Kang et al. · 2013 [cited by applicant]
US 20130267759A1 · Jin · 2013 [cited by applicant]
US 20130317569A1 · Deisseroth et al. · 2013 [cited by applicant]
US 20130328490A1 · Chen · 2013 [cited by applicant]
US 20130338738A1 · Garcia Molina et al. · 2013 [cited by applicant]
US 20140081347A1 · Nelson et al. · 2014 [cited by applicant]
US 20140135680A1 · Peyman · 2014 [cited by applicant]
US 20140194957A1 · Rubinfeld et al. · 2014 [cited by applicant]
US 20140200432A1 · Banerji et al. · 2014 [cited by applicant]
US 20140257438A1 · Simon et al. · 2014 [cited by applicant]
US 20140303025A1 · Van Keuren-Jensen et al. · 2014 [cited by applicant]
US 20140303424A1 · Glass · 2014 [cited by applicant]
US 20140316192A1 · De Zambotti et al. · 2014 [cited by applicant]
US 20140324138A1 · Wentz et al. · 2014 [cited by applicant]
US 20140330335A1 · Errico et al. · 2014 [cited by applicant]
US 20140336514A1 · Peyman · 2014 [cited by applicant]
US 20140347265A1 · Aimone et al. · 2014 [cited by applicant]
US 20150002025A1 · Maricic et al. · 2015 [cited by applicant]
US 20150088212A1 · De Ridder · 2015 [cited by applicant]
US 20150157604A1 · Morozova et al. · 2015 [cited by applicant]
US 20150196762A1 · Amurthur et al. · 2015 [cited by applicant]
US 20150235597A1 · Meng et al. · 2015 [cited by applicant]
US 20150305667A1 · Durand · 2015 [cited by applicant]
US 20150337030A1 · Abeliovich · 2015 [cited by applicant]
US 20150342495A1 · Davis et al. · 2015 [cited by applicant]
US 20160067087A1 · Tedford et al. · 2016 [cited by applicant]
US 20160091758A1 · Yoneyama · 2016 [cited by applicant]
US 20160220821A1 · O'Connell et al. · 2016 [cited by applicant]
US 20160235980A1 · Berman et al. · 2016 [cited by applicant]
US 20170072162A1 · Kim et al. · 2017 [cited by applicant]
US 20170082255A1 · Bentley et al. · 2017 [cited by applicant]
US 20170143966A1 · Reymers et al. · 2017 [cited by applicant]
US 20170151436A1 · Flaherty et al. · 2017 [cited by applicant]
US 20170182285A1 · Tyler et al. · 2017 [cited by applicant]
US 20170266443A1 · Rajguru et al. · 2017 [cited by applicant]
US 20180206737A1 · Colman · 2018 [cited by applicant]
US 20180236262A1 · Morries et al. · 2018 [cited by applicant]
US 20180277377A1 · Eto et al. · 2018 [cited by applicant]
US 20180286188A1 · Von Novak et al. · 2018 [cited by applicant]
US 20190030190A1 · Peyman · 2019 [cited by applicant]
US 20190076670A1 · Vyshedskiy · 2019 [cited by applicant]
US 20190126056A1 · Vlådila Bogdan · 2019 [cited by applicant]
US 20190215926A1 · Lay et al. · 2019 [cited by applicant]
US 20190254775A1 · Gregg et al. · 2019 [cited by applicant]
US 20190388020A1 · Stauch et al. · 2019 [cited by applicant]
US 20200038658A1 · Tyler et al. · 2020 [cited by applicant]
US 20200069808A1 · Luehr et al. · 2020 [cited by applicant]
US 20200269065A1 · Broeng et al. · 2020 [cited by applicant]
US 20200316334A1 · Tsai et al. · 2020 [cited by applicant]
US 20200316335A1 · Tsai et al. · 2020 [cited by applicant]
US 20210030998A1 · Wong · 2021 [cited by applicant]
US 20210121713A1 · Malchano et al. · 2021 [cited by applicant]
US 20210339043A1 · Malchano et al. · 2021 [cited by applicant]
US 20220008746A1 · Malchano et al. · 2022 [cited by applicant]
US 20220040496A1 · Adaikkan et al. · 2022 [cited by applicant]
US 20220151864A1 · Tsai et al. · 2022 [cited by applicant]
US 20220233879A1 · Tsai et al. · 2022 [cited by applicant]
US 20230173295A1 · Kim et al. · 2023 [cited by applicant]
US 20230181905A1 · Tsai et al. · 2023 [cited by applicant]
US 20240293680A1 · Malchano et al. · 2024 [cited by applicant]
US 20240325780A1 · Malchano et al. · 2024 [cited by applicant]
US 20250001203A1 · Malchano et al. · 2025 [cited by applicant]
AU 2018347870A1 · 2020 [cited by applicant]
CA 2979687A1 · 2016 [cited by applicant]
CA 3078704A1 · 2019 [cited by applicant]
CN 102791332A · 2012 [cited by applicant]
CN 103298480A · 2013 [cited by applicant]
CN 103492564A · 2014 [cited by applicant]
CN 104039353A · 2014 [cited by applicant]
CN 104783788A · 2015 [cited by applicant]
CN 103932701B · 2015 [cited by applicant]
CN 105278387A · 2016 [cited by applicant]
CN 106103711A · 2016 [cited by applicant]
CN 107002076A · 2017 [cited by applicant]
CN 111655319A · 2020 [cited by applicant]
EP 0911398A3 · 2003 [cited by applicant]
EP 1642609A1 · 2006 [cited by applicant]
EP 2075035A1 · 2009 [cited by applicant]
EP 2489402A2 · 2012 [cited by applicant]
EP 3694593A1 · 2020 [cited by applicant]
EP 3694464A4 · 2021 [cited by applicant]
EP 3541467B1 · 2024 [cited by applicant]
IT RM20090027A1 · 2010 [cited by applicant]
JP H08150210A · 1996 [cited by applicant]
JP 2006525039A · 2006 [cited by applicant]
JP 2008520280A · 2008 [cited by applicant]
JP 2011514194A · 2011 [cited by applicant]
JP 2014071825A · 2014 [cited by applicant]
JP 2015519096A · 2015 [cited by applicant]
JP 2018525754A · 2018 [cited by applicant]
KR 20020025884A · 2002 [cited by applicant]
KR 20130101596A · 2013 [cited by applicant]
KR 20140144272A · 2014 [cited by applicant]
KR 20160017099A · 2016 [cited by applicant]
KR 20160129752A · 2016 [cited by applicant]
WO WO9716196A1 · 1997 [cited by applicant]
WO WO0184141A1 · 2001 [cited by applicant]
WO WO2006055582A2 · 2006 [cited by applicant]
WO WO2007062367A2 · 2007 [cited by applicant]
WO WO2008041129A2 · 2008 [cited by applicant]
WO WO2008101128A1 · 2008 [cited by applicant]
WO WO2008147958A1 · 2008 [cited by applicant]
WO WO2010123577A2 · 2010 [cited by applicant]
WO WO2011042908A1 · 2011 [cited by applicant]
WO WO2011057028A1 · 2011 [cited by applicant]
WO WO2012024243A1 · 2012 [cited by applicant]
WO WO2013061597A1 · 2013 [cited by applicant]
WO WO2013152348A1 · 2013 [cited by applicant]
WO WO2014040175A1 · 2014 [cited by applicant]
WO WO2014107795A1 · 2014 [cited by applicant]
WO WO2014130960A1 · 2014 [cited by applicant]
WO WO2014162271A2 · 2014 [cited by applicant]
WO WO2014179331A2 · 2014 [cited by applicant]
WO WO2015034673A1 · 2015 [cited by applicant]
WO WO2015066679A2 · 2015 [cited by applicant]
WO WO2015149170A1 · 2015 [cited by applicant]
WO WO2017091698A1 · 2017 [cited by applicant]
WO WO2017091758A1 · 2017 [cited by applicant]
WO WO2017172728A1 · 2017 [cited by applicant]
WO WO2018094226A1 · 2018 [cited by applicant]
WO WO2019046338A1 · 2019 [cited by applicant]
WO WO2019074637A1 · 2019 [cited by applicant]
WO WO2019075094A1 · 2019 [cited by applicant]
WO WO2019241430A2 · 2019 [cited by applicant]
WO WO2020041502A1 · 2020 [cited by applicant]
WO WO2021216957A1 · 2021 [cited by applicant]
WO WO2021221879A1 · 2021 [cited by applicant]
WO WO2022027030A1 · 2022 [cited by applicant]
WO WO2022192277A1 · 2022 [cited by applicant]
“40hz Light Therapy addressing Alzheimer's news!” Indiegogo https://www.indiegogo.com/projects/40hz-light-therapy-addressing-alzheimer-s-news#/, https://www.indiegogo.com, Internet Archive Wayback Machine earliest Inter… [cited by applicant]
Adaikkan et al.: Gamma entrainment binds higher-order brain regions and offers neuroprotection. Neuron 102.5 (2019): 929-943. [cited by applicant]
Alzheimer's Life Therapy App. Apple Store. Current version 1.5.7 released Aug. 6, 2019, earliest version 1.0.3 released Jan. 17, 2018. Accessed at https://apps.apple.com/us/app/alzheimers-light-therapy/id1327175926. 3 p… [cited by applicant]
Aronov, D. et al., “Engagement of neural circuits underlying 2D spatial navigation in a rodent virtual reality system,” Neuron, vol. 84 (Oct. 2014): 442-456. [cited by applicant]
Barton, A. “Sound vibration treatment may boost brain activity in Alzheimer's patients,” The Globe and Mail (2016): http://www.theglobeandmail.com/life/health-and-fitness/health/sound-vibration-treatment-may-boost-brain… [cited by applicant]
Bartos, M. et al., “Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks,” Nature Reviews Neuroscience, vol. 8 (Jan. 2007): 45-56. [cited by applicant]
Basar, E. et al., “Delay of cognitive gamma responses in Alzheimer's disease,” Neurolmage: Clinical, vol. 11 (2016): 106-115. [cited by applicant]
Bebop. Mace Virtual Labs. Accessed at https://www.macevl.com/bebop on Nov. 18, 2020. 4 pages. [cited by applicant]
Berman et al., Chapter 32—Noninvasive neurotherapeutic treatment of neurodegeneration: integrating photobiomodulation and neurofeedback training in Photobiomodulation in the Brain Low-Level Laser (Light) Therapy in Neur… [cited by applicant]
Berman et al., Chapter 4—Photobiomodulation and Other Light Stimulation Procedures in Rhythmic Stimulation Procedures in Neuromodulation 2017, pp. 97-129. [cited by applicant]
Berman et al., “Photobiomodulation with near infrared light helmet in a pilot, placebo controlled clinical trial in dementia patients testing memory and cognition.” Journal of neurology and neuroscience 8.1 (2017). 15 p… [cited by applicant]
Bero, A. et al., “Neuronal activity regulates the regional vulnerability to amyloid-β deposition,” Nature Neuroscience, vol. 14 (May 2011): 750-756. [cited by applicant]
Boissonneault, V. et al., “Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease,” Brain, vol. 132 (Apr. 2009): 1078-1092. [cited by applicant]
Bragin, A. et al., “Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat,” Journal of Neuroscience, vol. 15 (Jan. 1995): 47-60. [cited by applicant]
“Brainsway: Deep TMS Therapy,” Brainsway (2014): http://www.brainsway.com/us. [cited by applicant]
Briones et al., “Dysregulation in myelination mediated by persistent neuroinflammation: possible mechanisms in chemotherapy-related cognitive impairment” Brain, behavior, and immunity 35 (2014): 23-32. [cited by applicant]
Busche, M. et al., “Decreased amyloid-B and increased neuronal hyperactivity by immunotherapy in Alzheimer's models,” Nature Neuroscience, vol. 18 (Dec. 2015): 1725-1727. [cited by applicant]
Buzsaki et al., “Mechanisms of Gamma Oscillations,” Rev. Neurosci. 35, 203-25 (2012). [cited by applicant]
Buzsaki, G. et al., “Scaling brain size, keeping timing: evolutionary preservation of brain rhythms,” Neuron, vol. 80 (Oct. 2013): 751-764. [cited by applicant]
Buzsaki, G. et al., “Hippocampal network patterns of activity in the mouse,” Neuroscience, vol. 116 (2003): 201-211. [cited by applicant]
Buzsaki, G. “Theta oscillations in the hippocampus,” Neuron, vol. 33 (Jan. 2002): 325-340. [cited by applicant]
Buzsaki. Rhythms of the Brain. New York: Oxford University Press. (465 pgs) (2006). [cited by applicant]
Cardin, J. et al., “Driving fast-spiking cells induces gamma rhythm and controls sensory responses,” Nature, vol. 459 (Apr. 2009): 663-667. [cited by applicant]
Carr, M. et al., “Hippocampal replay in the awake state: a potential substrate for memory consolidation and retrieval,” Nature Neuroscience, vol. 14 (Feb. 2011): 147-153. [cited by applicant]
Carr, M. et al., “Transient slow gamma synchrony underlies hippocampal memory replay,” Neuron, vol. 75 (Aug. 2012): 700-713. [cited by applicant]
Cataldo et al.: Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 157(1):277-… [cited by applicant]
Chitu, V. et al., “Colony-stimulating factor-1 in immunity and inflammation,” Current Opinion in Immunology, vol. 18 (Feb. 2006): 39-48. [cited by applicant]
Chiu, et al. (2013). A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385-401. [cited by applicant]
Chiu et al., “Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice.” Oncotarget 9.85 (2018): 35581. 17 pages. [cited by applicant]
Chung, et al. Structural and molecular interrogation of intact biological systems. Nature. May 16, 2013;497(7449):332-7. doi: 10.1038/nature12107. Epub Apr. 10, 2013. [cited by applicant]
Cirrito, J. et al., “In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life,” The Journal of Neuroscience, vol. 23 (Oct. 2003): 8844-… [cited by applicant]
Clements-Cortes, A. “Sound Stimulation in Patients With Alzheimer's Disease,” Annals of Long-Term Care: Clinical Care and Aging, vol. 23 (May 2015): 10-16. [cited by applicant]
Clements-Cortes et al., “Short-term effects of rhythmic sensory stimulation in Alzheimer's disease: An exploratory pilot study.” Journal of Alzheimer's Disease 52.2 (2016): 651-660. [cited by applicant]
Colgin, L. et al., “Frequency of gamma oscillations routes flow of information in the hippocampus,” Nature, vol. 462 (Nov. 2009): 353-357. [cited by applicant]
Colgin, L. et al., “Gamma oscillations in the hippocampus,” Physiology, vol. 25 (Oct. 2010): 319-329. [cited by applicant]
Correa et al., “A prospective evaluation of changes in brain structure and cognitive functions in adult stem cell transplant recipients.” Brain imaging and behavior 7.4 (2013): 478-490. [cited by applicant]
Corrected Notice of Allowance for U.S. Appl. No. 16/427,276, dated May 6, 2020. [cited by applicant]
Cronk, J. et al., “Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli,” Immunity, vol. 42 (Apr. 2015): 679-691. [cited by applicant]
Crotti et al., Mutant Huntingtin Promotes Autonomous Microglia Activation Via Myeloid Lineage-Determining Factors, Nature Neuroscience, vol. 17, pp. 513-521, 2014. [cited by applicant]
Das, U. et al., “Activity-induced convergence of App and Bace-1 in acidic microdomains via an endocytosis-dependent pathway,” Neuron, vol. 79 (Aug. 2013): 447-460. [cited by applicant]
Eckhorn, R. et al., “Coherent Oscillations: a Mechanism of Feature Linking in the Visual Cortex,” Biological Cybernetics, vol. 60 (1988): 121-130. [cited by applicant]
EP18866506.1 Communciation pursuant to Article 94(3) dated Oct. 14, 2023. [cited by applicant]
EP23150106.5 Extended European Search Report dated Jul. 5, 2023. [cited by applicant]
Erny et al., Host Microbiota Constantly Control Maturation And Function of Microglia In The CNS, Nature Neuroscience, vol. 18, pp. 965-977, 2015. [cited by applicant]
Final Office Action dated Dec. 7, 2023 issued in U.S. Appl. No. 17/320,632. [cited by applicant]
Final Office Action dated Jan. 17, 2024 issued in U.S. Appl. No. 17/486,165. [cited by applicant]
Final Office Action dated Jun. 4, 2018 for U.S. Appl. No. 15/360,637, 11 pages. [cited by applicant]
Fisher Wallace Stimulator http.//www.fisherwallace.com/, Internet Archive Wayback Machine earliest Internet archived date Jul. 13, 2017, 7 pages. Accessed May 2023. [cited by applicant]
Foster, D. et al., “Reverse replay of behavioural sequences in hippocampal place cells during the awake state,” Nature, vol. 440 (Mar. 2006):680-683. [cited by applicant]
Fries, P. et al., “The gamma cycle,” Trends in Neurosciences, vol. 30 (Jul. 2007): 309-316. [cited by applicant]
Geraghty et al. Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment. Neuron 103(2):250-265.e8 (Jul. 17, 2019). Epub May 20, 2019. doi: 10.1016/j.neuron.2019.04.032. [cited by applicant]
Gibson et al., “Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment.” Cell 176.1-2 (2019): 43-55. [cited by applicant]
Gibson et al., “Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain.” Science 344.6183 (2014). 27 pages. [cited by applicant]
Gillepsie, A. et al., “Apolipoprotein E4 Causes Age-Dependent Disruption of Slow Gamma Oscillations during Hippocampal Sharp-Wave Ripples,” Neuron, vol. 90 (May 2016): 740-751. [cited by applicant]
Gjoneska, E. et al., “Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease,” Nature, vol. 518 (Feb. 2015): 365-369. [cited by applicant]
“Good Vibrations Can Help Alzheimer's Patients,” Awakening from Alzheimer's http://www.awakeningfromalzheimers.com/good-vibrations-can-help-alzheimers-patients/, Internet Archive Wayback Machine earliest Internet archiv… [cited by applicant]
Gosselin et al., Environment Drives Selection And Function Of Enhancers Controlling Tissue-Specific Macrophage Identities, Cell, vol. 159, pp. 1327-1340, 2014. [cited by applicant]
Goutagny, R. et al., “Alterations in hippocampal network oscillations and theta-gamma coupling arise before Aβ overproduction in a mouse model of Alzheimer's disease,” European Journal of Neuroscience, vol. 37 (Jun. 201… [cited by applicant]
Gray, C. et al., “Chattering cells: superficial pyramidal neurons contributing to the generation of synchronous oscillations in the visual cortex,” Science, vol. 274 (Oct. 1996): 109-113. [cited by applicant]
Gray, C. et al., “Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties,” Nature, vol. 338 (Mar. 1989): 334-337. [cited by applicant]
Gualdi, Giulio et al.: Wound Repair and Extremely Low Frequency-Electromagnetic Field: Insight from In Vitro Study and Potential Clinical Application. Int. J. Mol. Sci. 2(9):5037. https://doi.org/10.3390/ijms22095037 (2… [cited by applicant]
Harvey, C. et al., “Intracellular dynamics of hippocampal place cells during virtual navigation,” Nature, vol. 461 (Oct. 2009): 941-946. [cited by applicant]
Helwig, M. et al., “The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins,” The Journal of Biological Chemistry, vol. 288 (Jan. 2013): 1114-1124. [cited by applicant]
Heneka, M. et al., “Innate immune activation in neurodegenerative disease,” Nature Reviews Immunology, vol. 14 (Jul. 2014): 463-477. [cited by applicant]
Hermelink, “Chemotherapy and cognitive function in breast cancer patients: the so-called chemo brain.” Journal of the National Cancer Institute Monographs 2015.51 (2015): 67-69. [cited by applicant]
Herrmann, C. et al., “Human EEG gamma oscillations in neuropsychiatric disorders,” Clinical Neurophysiology, vol. 116 (Dec. 2005): 2719-2733. Epub Oct. 25, 2005. [cited by applicant]
Herrmann, C. et al.: Human EEG responses to 1-100 Hz flicker: resonance phenomena in visual cortex and their potential correlation to cognitive phenomena. Experimental Brain Research 137:346-353 (2001). [cited by applicant]
Hsiao, F. et al., “Altered Oscillation and Synchronization of Default-Mode Network Activity in Mild Alzheimer's Disease Compared to Mild Cognitive Impairment: an Electrophysiological Study,” PLOS One, vol. 8 (Jul. 2013)… [cited by applicant]
Huang, S. et al., “Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages,” Nature Immunology, vol. 15 (Sep. 2014): 846-855. [cited by applicant]
Iaccarino et al. “Gamma frequency entrainment attenuates amyloid load and modifies microglia.” Nature 540.7632 (2016): 230-235. [cited by applicant]
Iliff, J. et al., “A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β,” Science Translational Medicine, vol. 4 (Aug. 2012): 147. [cited by applicant]
International Search Report and Written Opinion for International Appl. No. PCT/US2017/062328, mailed on May 3, 2018. [cited by applicant]
International Search Report and Written Opinion for International Appl. No. PCT/US2017/062333, mailed on Jun. 20, 2018. [cited by applicant]
International Search Report and Written Opinion for International Appl. No. PCT/US2017/062335, mailed on Apr. 12, 2018. [cited by applicant]
International Search Report and Written Opinion in International Patent Application No. PCT/US18/55258 mailed Dec. 27, 2018. 16 pages. [cited by applicant]
International Search Report and Written Opinion in International Patent Application No. PCT/US2018/051785, mailed on Jan. 24, 2019. [cited by applicant]
International Search Report and Written Opinion in International Patent Application No. PCT/US2021/028776 mailed Aug. 13, 2021, 19 pages. [cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for International Application No. PCT/US16/63536, dated Mar. 27, 2017, 19 pages. [cited by applicant]
International Search Report in PCT Application No. PCT/US2021/060146 mailed Feb. 11, 2022, 15 pages. [cited by applicant]
Israel, M. et al., “Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells,” Nature, vol. 482 (Jan. 2012): 216-220. [cited by applicant]
Jeong, J. “EEG dynamics in patients with Alzheimer's disease,” Clinical Neurophysiology, vol. 115 (Aug. 2004): 1490-1505. [cited by applicant]
Jiang et al., “PAN-811 prevents chemotherapy-induced cognitive impairment and preserves neurogenesis in the hippocampus of adult rats.” Plos one 13.1 (2018): e0191866. [cited by applicant]
Khasabova et al., “Pioglitazone, a PPARγ agonist, reduces cisplatin-evoked neuropathic pain by protecting against oxidative stress.” Pain 160.3 (2019): 688-701. [cited by applicant]
Koenig, T. et al., “Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment,” Neurobiology of Aging, vol. 26 (Feb. 2005): 165-171. [cited by applicant]
Kreutzberg, G. “Microglia: a sensor for pathological events in the CNS,” Trends in Neurosciences, vol. 19 (Sep. 1996): 312-318. [cited by applicant]
Krynetskiy et al., “Establishing a model for assessing DNA damage in murine brain cells as a molecular marker of chemotherapy-associated cognitive impairment.” Life sciences 93.17 (2013): 605-610. [cited by applicant]
Kumburovic et al., “Antioxidant effects of [cited by applicant]
Kurudenkandy, F. et al., “Amyloid-β-Induced Action Potential Desynchronization and Degradation of Hippocampal Gamma Oscillations Is Prevented by Interference with Peptide Conformation Change and Aggregation,” The Journa… [cited by applicant]
Laumet et al., “Cisplatin educates CD8+ T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice.” Pain 160.6 (2019): 1459. 19 pages. [cited by applicant]
Leinenga, G. et al., “Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model,” Science Translational Medicine, vol. 7 (Mar. 2015): 278. [cited by applicant]
Leo et al., “Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium channels in dorsal root ganglion neurons.” Experimental neurology 288 (2017): 62-74. [cited by applicant]
Li, F. et al., “Effect of electroacupuncture stimulation of “Baihui” (GV 20) and “Yongquan” (KI 1) on expression of hippocampal amyloid-β and low density lipoprotein receptor-related protein-1 in APP/PS 1 transgenic mic… [cited by applicant]
Lok, K. et al., “Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background,” Neuroscience Letters, vol. 557 (Dec. 2013): 84-89. [cited by applicant]
Martorell et al.: Multi-sensory gamma stimulation ameliorates Alzheimer's-associated pathology and improves cognition. Cell 177.2: 256-271 (2019). [cited by applicant]
Martorell et al., Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition. Cell. Mar. 14, 2019. https://doi.org/10.1016/j.cell.2019.02.014. [cited by applicant]
Mastrangelo, M. et al., “Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice,” BMC Neuroscience, vol. 9 (Aug. 2008)… [cited by applicant]
Mcfadden; Kristina L. et al.: Test-Retest Reliability of the 40 Hz EEG Auditory Steady-State Response. Plos One, Published: Jan. 22, 2014. https://doi.org/10.1371/journal.pone.0085748. [cited by applicant]
Meyers, “How chemotherapy damages the central nervous system.” Journal of biology 7.4 (2008): 11. 3 pages. [cited by applicant]
Mind Alive Inc. http://mindalive.com/ Internet Archive Wayback Machine earliest Internet archived date Mar. 2, 2001, 2 pages. [cited by applicant]
Mind Gear http://Mindlightz.com, Internet Archive Wayback Machine earliest Internet archived date Mar. 1, 2015, 5 pages. [cited by applicant]
Mind Machines http://www.mindmachines.com/: Internet Archive Wayback Machine earliest Internet archived date Dec. 7, 1998, 6 pages. [cited by applicant]
Mind Mods http://www.mindmods.com/, Internet Archive Wayback Machine earliest. Internet archived date Mar. 12, 2008, 2 pages. [cited by applicant]
Mind Place http://mindplace.com/, Internet Archive Wayback Machine earliest Internet archived date Dec. 2, 1998, 4 pages. [cited by applicant]
Mitrasinovic, O. et al., “Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Aβ,” Neurobiology of Aging, vol. 24 (Oct. 2003): 807-815. [cited by applicant]
Mosabbir et at “The effects of long-term 40-Hz physioacoustic vibrations on motor impairments in Parkinson's disease: a double-blinded randomized control trial.” Healthcare. vol. 8. No. 2. MDPI, 2020, 13 pages. [cited by applicant]
Neuro Alpha (Brain PBM). Vielight the Life Light 2019. Accessed at https://vielight.com/devices/vielight-neuro-alpha/ on Aug. 22, 2019. 7 pages. [cited by applicant]
Neuronix http://neuronixmedical.com, Internet Archive Wayback Machine earliest Internet archived date Nov. 16, 2009, 2 pages. [cited by applicant]
Neuronix http://neurotronics.eu/, Internet Archive Wayback Machine earliest Internet archived date Sep. 24, 2008, 2 pages. [cited by applicant]
Next Wave Physioacoustic MX therapy chair. Nextwave. Accessed at http://www.nextwaveworldwide.com/products/physioacoustic-mx-therapy-chair/ on Nov. 18, 2020. 2 pages. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 15/816,222, dated Jun. 15, 2018. [cited by applicant]
Notice of Allowance dated Jan. 10, 2019 issued in copending U.S. Appl. No. 15/816,233. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/415,825, dated Jul. 20, 2020. [cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 16/135,938 dated Sep. 21, 2021. [cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 16/156,833 dated Feb. 3, 2021. [cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 16/404,302 dated May 19, 2021. [cited by applicant]
Oakley, H. et al., “Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation,” Journal … [cited by applicant]
O'Connor et al., “The use of the puzzle box as a means of assessing the efficacy of environmental enrichment.” JoVE (Journal of Visualized Experiments) 94 (2014): e52225. 8 pages. [cited by applicant]
Office Action dated Sep. 21, 2018 issued in copending U.S. Appl. No. 15/816,233. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/404,302, dated Jul. 24, 2020. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/415,825, dated Jan. 27, 2020. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/901,628 dated May 23, 2024. [cited by applicant]
Office Action issued in U.S. Appl. No. 17/666,153 dated Sep. 16, 2024. [cited by applicant]
Ohmi et al. Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B. PLoS One 6:e27461 (2011). [cited by applicant]
Palop et al., Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease, Neuron, 55: 697-711 (2007). [cited by applicant]
Palpagama et al., “The role of microglia and astrocytes in Huntington's disease.” Frontiers in molecular neuroscience 12 (2019): 258. 15 pages. [cited by applicant]
Paro Therapeutic Robot http://www.parorobots.com/: Internet Archive Wayback Machine earliest Internet Archived date Dec. 4, 2008, 2 pages. [cited by applicant]
Pastor et al. “Activation of human cerebral and cerebellar cortex by auditory stimulation at 40 Hz.” Journal of Neuroscience 22.23 (2002): 10501-10506. [cited by applicant]
Pericic, D. et al., “Sex differences in the response to GABA antagonists depend on the route of drug administration,” Experimental Brain Research, vol. 115 (Jun. 1997): 187-190. [cited by applicant]
Poza et al. “Analysis of spontaneous MEG activity in patients with Alzheimer's disease using spectral entropies.” 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, … [cited by applicant]
“PSIO Manual,” PSiO http://www.psioplanet.com/download/manuals/manuel-psio-1.1-EN.pdf, http://www.psoplanet.com/, Internet Archive Wayback Machine earliest Internet archived date Mar. 2, 2013, 16 pages. [cited by applicant]
Quietmind Foundation Launches World's First Clinical Trial of Drug-Free Infrared Light Therapy to Treat Dementia. Global News Wire, Feb. 17, 2011. Accessed at http://www.globenewswire.com/news -release/2011/02/17/118291… [cited by applicant]
Raivich, G. et al., “Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function,” Brain Research Reviews, vol. 30 (Aug. 1999): 77-105. [cited by applicant]
Ravassard, P. et al., “Multisensory control of hippocampal spatiotemporal selectivity,” Science, vol. 340 (Jun. 2013): 1342-1346. [cited by applicant]
Santarnecchi “Individual differences and specificity of prefrontal gamma frequency-tACS on fluid intelligence capabilities.” Cortex 75 (2016): 33-43. [cited by applicant]
Sauer et al., “Impaired fast-spiking interneuron function in a genetic mouse model of depression,” eLIFE, vol. 4., Mar. 5, 2015, pp. 1-20. [cited by applicant]
Seibenhener et al., “Use of the open field maze to measure locomotor and anxiety-like behavior in mice.” JoVE (Journal of Visualized Experiments) 96 (2015): e52434. 9 pages. [cited by applicant]
Selkoe, D. et al., “The role of APP processing and trafficking pathways in the formation of amyloid beta-protein,” Annals of the New York Academy of Sciences (Jan. 1996): 57-64. [cited by applicant]
Siegle, J. et al., “Enhancement of Encoding and retrieval functions through theta phase-specific manipulation of hippocampus,” ELife Sciences Publications (Jul. 2014). [cited by applicant]
Smith et al., “The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.” Oncology nursing forum. vol. 38. No. 2. 2011. 10 pages. [cited by applicant]
Snailax Massage Mat with Heat. Snailax. Accessed at https://www.amazon.com/Snailax-Massage-Mat-Heat -Relaxation/dp/B07MNZ5Z6P on Nov. 18, 2020. 10 pages. [cited by applicant]
Stam, C. et al., “Generalized synchronization of MEG recordings in Alzheimer's Disease: evidence for involvement of the gamma band,” Journal of Clinical Neurophysiology, vol. 19 (Dec. 2002): 562-574. [cited by applicant]
Subramanian, Aravind, et al., Gene Set Enrichment Analysis: a Knowledge-based Approach for Interpreting Genome-wide Expression Profiles. Proceedings of the National Academy of Sciences of the United States of America 10… [cited by applicant]
Sudol, K. et al., “Generating Differentially Targeted Amyloid-β Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease,” Molecular Therapy, vol. 17 (Dec. 2009): 2031-2040. [cited by applicant]
Tanaka et al.: Analysis of MEG Auditory 40-Hz Response by Event-Related Coherence. ITEIS 125.6: 898-903 (2005). [cited by applicant]
Thakurela, S. et al., “Dynamics and function of distal regulatory elements during neurogenesis and neuroplasticity,” Genome Research, vol. 25 (Sep. 2015): 1309-1324. [cited by applicant]
Theragun by Therabody. Accessed at https://www.theragun.com/us/en-us/4th-generation-devices/ on Nov. 18, 2020. 26 pages. [cited by applicant]
Transparent Corporation https://www.transparentcorp.com/, Internet Archive Wayback Machine earliest Internet archived date Jan. 10, 1998, 3 pages. [cited by applicant]
Trapnell et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature protocols 7:562-578 (2012). [cited by applicant]
Trapnell, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. May 2010;28(5):511-5. doi: 10.1038/nbt.1621. Epub May… [cited by applicant]
Traub, R. et al., “Analysis of gamma rhythms in the rat hippocampus in vitro and in vivo,” the Journal of Physiology, vol. 493 (Jun. 1996): 471-484. [cited by applicant]
U.S. Appl. No. 16/901,628 Notice of Allowance dated Jun. 13, 2024. [cited by applicant]
U.S. Appl. No. 17/486,165 Office Action dated Jan. 17, 2024. [cited by applicant]
U.S. Appl. No. 18/821,576, filed Aug. 30, 2024. [cited by applicant]
U.S. Appl. No. 16/901,592 Notice of Allowance issued Aug. 8, 2024. [cited by applicant]
U.S. Appl. No. 16/901,592 Office Action dated Mar. 29, 2024. [cited by applicant]
U.S. Appl. No. 16/901,628 Office Action dated Dec. 15, 2023. [cited by applicant]
U.S. Appl. No. 16/919,975 Office Action dated Aug. 27, 2024. [cited by applicant]